Search results
Results from the WOW.Com Content Network
PFE earnings call for the period ending June 30, 2024. ... Good day, everyone, and welcome to Pfizer's second-quarter 2024 earnings conference call. Today's call is being recorded. At this time, I ...
Pfizer reports mixed second quarter earnings as uncertainty around COVID remains a headwind. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach ...
Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. ... It now projects full-year adjusted earnings between ...
Third, many investors still fail to appreciate the full potential of Pfizer’s oral GLP-1 drug candidate, danuglipron, which is on the verge of advancing to Phase 3 studies and is well positioned ...
Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the second quarter.
The company, raised its full-year guidance by $1.5 billion and beat Wall Street estimates in its third quarter earnings Tuesday. Pfizer now expects between $61 billion and $64 billion in revenue ...
As for earnings, Pfizer's non-GAAP (adjusted) bottom line flipped into the black. The company earned a profit of just over $6 billion, quite a change from the $968 million loss in the year-ago period.
Pfizer said Tuesday that it now expects adjusted earnings to range between $2.75 and $2.95 per share for 2024. That amounts to a 30 cent increase at the midpoint from a forecast the company made ...